PCR testing company Biomeme on Thursday reported an agreement to introduce its highly accurate, mobile RT-PCR COVID-19 test to BioIQ's COVID testing platform and on-site testing events with centralized access to registration, test scheduling and digital programme management, integrated telehealth consultation and follow-up for employers, health plans and consumers.

The partnership added that the field-ready testing solution has gold-standard sensitivity and specificity associated with lab-based RT-PCR tests and produces test results on several dozens of samples within two hours and over 1,500 samples in a standard eight-hour period. The solutions bring speed, scientific rigor and structure to worksite, retail and public health COVID testing events.

To control the devastating COVID-19 disease, Biomeme launched its portable platform of simple DNA/RNA extraction and purification, shelf-stable lyophilized real-time PCR assays, hand-held qPCR thermocyclers, mobile apps, a cloud portal and a robust web API.

BioIQ's COVID and infectious disease platform encompasses on-site, retail, and home self-collection workflows across a variety of test types, including nasal and saliva RT-PCR molecular tests, antigen tests, and antibody tests, all within a consumer-friendly digital experience.